Study on Using 18F-DCFPyL PET/MRI to Detect Tumors in Intermediate and High-Risk Prostate Cancer
Sponsor: Stanford University
ClinicalTrials ID:NCT04809584
This clinical trial is exploring whether a new type of scan, called 18F-DCFPyL PET/MRI, can better detect tumors in patients with intermediate or high-risk prostate cancer compared to standard scans.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The aim of this study is to find out if a new imaging technique, 18F-DCFPyL PET/MRI, can identify smaller tumors in patients with intermediate or high-risk prostate cancer. This technique combines a special radioactive agent with advanced imaging to potentially detect tumors that might be missed by regular CT or MRI scans.
Description
This study involves 100 participants who have been newly diagnosed with intermediate or high-risk prostate cancer. These participants are scheduled to have surgery to remove the prostate and nearby lymph nodes. The study will use a new imaging method, 18F-DCFPyL PET/MRI, to see if it can detect tumors more effectively than standard imaging techniques.
Eligibility Criteria
Inclusion Criteria
- Must be over 18 years old.
- Have a confirmed diagnosis of prostate cancer through a biopsy.
- Scheduled for surgery to remove the prostate and lymph nodes.
- Have intermediate to high-risk prostate cancer, indicated by factors like high PSA levels, advanced tumor stage, or a high Gleason score.
- Able to understand and sign a consent form.
- Have a performance status that allows for daily activities with some limitations.
Exclusion Criteria
- Have received chemotherapy or radiation therapy before surgery.
- Have undergone hormone therapy or other treatments before the PET scan.
- Have metal implants that prevent MRI scans.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Stanford University | 94304 | Stanford | California |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.